Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: Avoiding pitfalls in the risk calculations

✍ Scribed by Hodge, Susan E.; Lebo, Roger V.; Yesley, Anne R.; Cheney, Susan M.; Angle, Heide; Milunsky, Jeff

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 20 KB
• Volume: 82
• Category: Article
• ISSN: 0148-7299
• DOI: 10.1002/(sici)1096-8628(19990212)82:4<329::aid-ajmg10>3.0.co;2-d

✦ Synopsis

We describe a general approach to derive fetal risk following two separate test results that each raise the likelihood of the same fetal abnormality without clearly determining whether the abnormality exists. Echogenic bowel observed on fetal ultrasonography may have multiple causes, including an a priori risk of approximately 1% of cystic fibrosis (CF). On numerous occasions our laboratory tests have detected only normal cystic fibrosis transmembrane regulator (CFTR) alleles in fetuses with echogenic bowel. This result indicates that another cause most likely explains the abnormal ultrasound finding. One of our tested fetuses was heterozygous for the ⌬F508 CFTR mutation and had a normal karyotype. Over 770 CFTR mutations have been described, and a significant proportion of parental mutant alleles could not be detected by our 25mutation test. Further mutation analysis demonstrated that the fetus' mother carried the ⌬F508 mutation but the father (of different ethnic background than the mother) did not carry a detectable mutation. Thus, this test result substantially increased the risk of the fetus having CF, while still not giving a definitive answer to whether the fetus was affected. A rigorous mathematical analysis determined that the 1% risk of CF following ultrasound study was increased to slightly under 12% following DNA analysis. The case is described, and the mathematical formulas are explained and illustrated with examples, along with a review of conditional probability (Appendix 2). Am.